MCID: MYL004
MIFTS: 53

Myelodysplastic Myeloproliferative Cancer

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Myelodysplastic Myeloproliferative Cancer

MalaCards integrated aliases for Myelodysplastic Myeloproliferative Cancer:

Name: Myelodysplastic Myeloproliferative Cancer 38 12
Myelodysplastic/myeloproliferative Neoplasm 12 53 15
Myelodysplastic-Myeloproliferative Diseases 44 73
Myeloproliferative/myelodysplastic Syndromes 12
Myelodysplastic Myeloproliferative Disease 12
Myelodysplastic/myeloproliferative Disease 53

Classifications:



External Ids:

Disease Ontology 12 DOID:4972
MeSH 44 D054437
NCIt 50 C27262
SNOMED-CT 68 397336008 445738007
ICD10 33 C94.6
UMLS 73 C1301355

Summaries for Myelodysplastic Myeloproliferative Cancer

NIH Rare Diseases : 53 Myelodysplastic/myeloproliferative diseases are a group of diseases of the blood and bone marrow in which the bone marrow makes too many white blood cells.  These disease have features of both myelodysplastic syndromes and myeloproliferative disorders. In myelodysplastic diseases, the blood stem cells do not mature into healthy red blood cells, white blood cells, or platelets and as a result, there are fewer of these healthy cells. In myeloproliferative diseases, a greater than normal number of blood stem cells develop into one or more types of blood cells and the total number of blood cells slowly increases. The 3 main types of myelodysplastic/myeloproliferative diseases include chronic myelomonocytic leukemia (CMML); juvenile myelomonocytic leukemia (JMML); and atypical chronic myelogenous leukemia (aCML). When a myelodysplastic/myeloproliferative disease does not match any of these types, it is called myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC). Symptoms of CMML and JMML may include fever, feeling tired and weight loss. Symptoms of aCML may include easy bruising or bleeding and feeling tired or weak. Myelodysplastic/myeloproliferative diseases may progress to acute leukemia. There are different types of treatment for individuals with one of these diseases, which may include chemotherapy, another drug therapy, stem cell transplant and/or supportive care.

MalaCards based summary : Myelodysplastic Myeloproliferative Cancer, also known as myelodysplastic/myeloproliferative neoplasm, is related to atypical chronic myeloid leukemia and myeloproliferative neoplasm. An important gene associated with Myelodysplastic Myeloproliferative Cancer is PTPN11 (Protein Tyrosine Phosphatase, Non-Receptor Type 11), and among its related pathways/superpathways are Developmental Biology and PAK Pathway. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are endocrine/exocrine gland and cellular

Disease Ontology : 12 A myeloid neoplasm that results in the overproduction of white blood cells.

Wikipedia : 76 Myelodysplastic–myeloproliferative diseases are a category of hematological malignancies disorders... more...

Related Diseases for Myelodysplastic Myeloproliferative Cancer

Diseases related to Myelodysplastic Myeloproliferative Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 atypical chronic myeloid leukemia 31.2 ASXL1 CSF3R JAK2 SETBP1
2 myeloproliferative neoplasm 30.9 JAK2 PTPN11 TET2
3 thrombocytosis 29.7 CSF2 JAK2 TET2
4 refractory anemia 29.6 ASXL1 JAK2 TET2
5 myelofibrosis 28.8 ASXL1 HRAS JAK2 TET2
6 leukemia 28.4 CSF2 CSF3R JAK2 NF1 NRAS PTPN11
7 myeloid leukemia 27.5 CSF2 CSF3R HRAS JAK2 NRAS PTPN11
8 myelodysplastic syndrome 25.6 ASXL1 CSF2 CSF3R HRAS JAK2 NF1
9 leukemia, acute myeloid 24.6 ASXL1 CSF2 CSF3R HRAS JAK2 NRAS
10 unclassified myelodysplastic/myeloproliferative disease 12.2
11 autosomal dominant café au lait spots 10.7 NF1 PTPN11
12 neurofibromatosis-noonan syndrome 10.6 NF1 PTPN11
13 giant congenital nevus 10.6 HRAS NRAS
14 malignant spindle cell melanoma 10.6 NF1 NRAS
15 benign struma ovarii 10.5 HRAS NRAS
16 schimmelpenning-feuerstein-mims syndrome 10.5 HRAS NRAS
17 ovarian melanoma 10.5 HRAS NRAS
18 malignant conjunctival melanoma 10.5 HRAS NRAS
19 melanomatosis 10.5 HRAS NRAS
20 marcus gunn phenomenon 10.5 HRAS NRAS
21 malignant struma ovarii 10.4 HRAS NRAS
22 mucosal melanoma 10.4 NF1 NRAS
23 meningeal melanomatosis 10.4 HRAS NRAS
24 nevus, epidermal 10.4 HRAS NRAS
25 legius syndrome 10.4 NF1 PTPN11
26 melanocytic nevus syndrome, congenital 10.4 HRAS NRAS
27 acneiform dermatitis 10.3 HRAS NRAS
28 myelophthisic anemia 10.3 JAK2 PTPN11
29 sporadic pheochromocytoma 10.2 HRAS NF1
30 leopard syndrome 10.2 HRAS NF1 PTPN11
31 pulmonic stenosis 10.2 HRAS NF1 PTPN11
32 vulvar melanoma 10.2 HRAS NF1 NRAS
33 neurofibromatosis, type iv, of riccardi 10.2 HRAS NF1 PTPN11
34 pilocytic astrocytoma 10.2 HRAS NF1 PTPN11
35 splenomegaly 10.2 JAK2 SETBP1
36 malignant skin fibrous histiocytoma 10.2 HRAS NRAS
37 refractory anemia with excess blasts 10.2 ASXL1 SETBP1 TET2
38 liver angiosarcoma 10.1 HRAS NRAS
39 acute promyelocytic leukemia 10.0
40 pyridoxine-refractory autosomal recessive sideroblastic anemia 10.0
41 acquired idiopathic sideroblastic anemia 10.0
42 malignant dermis tumor 10.0 HRAS NRAS
43 chronic neutrophilic leukemia 9.9 ASXL1 CSF3R SETBP1
44 noonan syndrome 1 9.9 HRAS NF1 NRAS PTPN11
45 core binding factor acute myeloid leukemia 9.8 HRAS JAK2 NRAS
46 myeloma, multiple 9.8 CSF2 HRAS NRAS PTPN11
47 exophthalmos 9.7 ASXL1 NF1
48 neutrophilia, hereditary 9.6 CSF2 CSF3R JAK2
49 essential thrombocythemia 9.6 ASXL1 JAK2 TET2
50 chronic myelomonocytic leukemia 9.4 ASXL1 JAK2 SETBP1 TET2

Graphical network of the top 20 diseases related to Myelodysplastic Myeloproliferative Cancer:



Diseases related to Myelodysplastic Myeloproliferative Cancer

Symptoms & Phenotypes for Myelodysplastic Myeloproliferative Cancer

MGI Mouse Phenotypes related to Myelodysplastic Myeloproliferative Cancer:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.09 ASXL1 CSF2 CSF3R HRAS JAK2 NF1
2 cellular MP:0005384 10.08 ASXL1 CSF2 CSF3R JAK2 NF1 NRAS
3 cardiovascular system MP:0005385 10.04 CSF2 CSF3R HRAS NF1 NRAS PTPN11
4 hematopoietic system MP:0005397 10.01 ASXL1 CSF2 CSF3R NF1 NRAS PTPN11
5 immune system MP:0005387 9.97 ASXL1 CSF2 CSF3R JAK2 NF1 NRAS
6 craniofacial MP:0005382 9.93 ASXL1 CSF2 HRAS NF1 NRAS PTPN11
7 integument MP:0010771 9.87 JAK2 NF1 NRAS PTPN11 RARS CSF2
8 mortality/aging MP:0010768 9.85 ASXL1 CSF2 CSF3R HRAS JAK2 NF1
9 liver/biliary system MP:0005370 9.73 ASXL1 JAK2 NF1 NRAS PTPN11 TET2
10 neoplasm MP:0002006 9.56 CSF2 HRAS JAK2 NF1 NRAS PTPN11
11 skeleton MP:0005390 9.17 ASXL1 CSF2 HRAS JAK2 NF1 NRAS

Drugs & Therapeutics for Myelodysplastic Myeloproliferative Cancer

Drugs for Myelodysplastic Myeloproliferative Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 389)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
8
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
9
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
12
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 135968-09-1
13
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
15
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
16
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
17
Vidarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 24356-66-9 32326 21704
18
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
19
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
20
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
21
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
22
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
23
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
24
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 65271-80-9 4212
25
Thioguanine Approved Phase 3 154-42-7 2723601
26
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
27
Ephedrine Approved Phase 3 299-42-3 9294
28
Pseudoephedrine Approved Phase 3 90-82-4 7028
29
Amitriptyline Approved Phase 3 50-48-6 2160
30
Baclofen Approved Phase 3 1134-47-0 2284
31
Perphenazine Approved Phase 3 58-39-9 4748
32
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
33
Acyclovir Approved Phase 3 59277-89-3 2022
34
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
35
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
36
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
37
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-02-2 5743
38
Allopurinol Approved Phase 3,Phase 2,Phase 1 315-30-0 2094
39
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
40
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
41
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
42
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
43
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
44
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
45
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
46 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Not Applicable 979-32-8
47
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
48
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
49
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
50
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2

Interventional clinical trials:

(show top 50) (show all 419)
# Name Status NCT ID Phase Drugs
1 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
3 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
6 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
7 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
8 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Completed NCT00075816 Phase 3
9 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
10 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
14 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
15 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
16 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
17 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
18 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
19 Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
22 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
23 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
24 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
25 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
26 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
27 Study of ASTX727 vs IV Decitabine in MDS and CMML Recruiting NCT03306264 Phase 3 ASTX727;Dacogen
28 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
29 Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Recruiting NCT02214407 Phase 3 Decitabine;HYDROXYUREA
30 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Recruiting NCT02907359 Phase 3 Guadecitabine
31 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
32 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
33 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
34 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
35 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
36 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
37 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
38 Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
39 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Terminated NCT00450450 Phase 3
40 Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Terminated NCT00109538 Phase 3 Lonafarnib
41 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
42 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
43 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
44 Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Unknown status NCT00044954 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
45 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
46 Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid
47 Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome Unknown status NCT01772420 Phase 2 Eltrombopag Olamine;Lenalidomide
48 Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure Unknown status NCT01133886 Phase 2 Decitabine
49 A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q Unknown status NCT00885508 Phase 2 Lenalidomide
50 Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes Completed NCT00098683 Phase 2 amifostine trihydrate

Search NIH Clinical Center for Myelodysplastic Myeloproliferative Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Myelodysplastic Myeloproliferative Cancer:
NiCord
Embryonic/Adult Cultured Cells Related to Myelodysplastic Myeloproliferative Cancer:
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: myelodysplastic-myeloproliferative diseases

Genetic Tests for Myelodysplastic Myeloproliferative Cancer

Anatomical Context for Myelodysplastic Myeloproliferative Cancer

MalaCards organs/tissues related to Myelodysplastic Myeloproliferative Cancer:

41
Myeloid, Bone, Bone Marrow, T Cells, Kidney, Liver, Neutrophil

Publications for Myelodysplastic Myeloproliferative Cancer

Articles related to Myelodysplastic Myeloproliferative Cancer:

(show all 21)
# Title Authors Year
1
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. ( 29465270 )
2018
2
Atypical chronic myeloid leukaemia - aA rare subtype of myelodysplastic/myeloproliferative neoplasm. ( 29692658 )
2018
3
Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms. ( 28626218 )
2017
4
Suspected myelodysplastic/myeloproliferative neoplasm in a feline leukemia virus-negative cat. ( 27870069 )
2016
5
Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia. ( 27240832 )
2016
6
Targeted re-sequencing of TET2 in Taiwanese patients with myelodysplastic/myeloproliferative neoplasms. ( 27418193 )
2016
7
Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnosticA principles and upcoming updates. ( 27161873 )
2016
8
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. ( 25624319 )
2015
9
NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. ( 25813079 )
2015
10
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. ( 24627528 )
2014
11
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. ( 22929973 )
2013
12
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). ( 22180010 )
2012
13
Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice. ( 21205929 )
2011
14
Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. ( 21502425 )
2011
15
A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course. ( 21635206 )
2011
16
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. ( 21998214 )
2011
17
Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. ( 20421268 )
2010
18
Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders. ( 20670271 )
2010
19
Therapy-related myelodysplastic/myeloproliferative neoplasms with del(5q) and t(1;11)(p32;q23) lacking MLL rearrangement. ( 20519822 )
2010
20
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. ( 19372255 )
2009
21
Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification. ( 20309429 )
2009

Variations for Myelodysplastic Myeloproliferative Cancer

Expression for Myelodysplastic Myeloproliferative Cancer

Search GEO for disease gene expression data for Myelodysplastic Myeloproliferative Cancer.

Pathways for Myelodysplastic Myeloproliferative Cancer

Pathways related to Myelodysplastic Myeloproliferative Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 CSF2 HRAS JAK2 NF1 NRAS PTPN11
2
Show member pathways
13.09 CSF2 CSF3R HRAS JAK2 NRAS PTPN11
3
Show member pathways
13.06 CSF2 CSF3R HRAS JAK2 NF1 NRAS
4
Show member pathways
12.76 CSF2 HRAS NRAS PTPN11
5 12.72 CSF3R HRAS JAK2 NRAS
6
Show member pathways
12.65 HRAS JAK2 NF1 NRAS
7
Show member pathways
12.6 HRAS NF1 NRAS PTPN11
8
Show member pathways
12.44 HRAS JAK2 NRAS PTPN11
9
Show member pathways
12.44 CSF2 HRAS NRAS PTPN11
10
Show member pathways
12.42 CSF2 HRAS JAK2 NRAS
11
Show member pathways
12.34 CSF2 HRAS NRAS PTPN11
12
Show member pathways
12.31 HRAS JAK2 NRAS PTPN11
13
Show member pathways
12.25 CSF2 HRAS NRAS PTPN11
14
Show member pathways
12.21 HRAS JAK2 NF1 PTPN11
15 12.2 HRAS NRAS PTPN11
16
Show member pathways
12.18 HRAS NRAS PTPN11
17
Show member pathways
12.13 HRAS NRAS PTPN11
18 12.11 HRAS NRAS PTPN11
19
Show member pathways
12.1 HRAS NRAS PTPN11
20
Show member pathways
12.1 HRAS JAK2 NF1 NRAS
21 12.08 HRAS JAK2 PTPN11
22
Show member pathways
12.07 HRAS JAK2 PTPN11
23
Show member pathways
12.03 CSF2 JAK2 PTPN11
24
Show member pathways
12.02 HRAS NRAS PTPN11
25 11.99 HRAS JAK2 PTPN11
26
Show member pathways
11.99 HRAS JAK2 NRAS PTPN11
27 11.97 HRAS JAK2 NRAS
28
Show member pathways
11.95 HRAS JAK2 PTPN11
29
Show member pathways
11.95 HRAS JAK2 NRAS PTPN11
30
Show member pathways
11.95 CSF2 CSF3R HRAS JAK2 PTPN11
31
Show member pathways
11.93 HRAS NF1 NRAS
32 11.85 HRAS NF1 NRAS
33
Show member pathways
11.84 HRAS JAK2 PTPN11
34
Show member pathways
11.83 HRAS JAK2 NRAS
35 11.76 HRAS JAK2 NRAS
36
Show member pathways
11.76 HRAS JAK2 NF1 NRAS
37
Show member pathways
11.74 HRAS JAK2 PTPN11
38 11.51 HRAS NF1 NRAS PTPN11
39
Show member pathways
11.5 HRAS JAK2 NRAS
40 11.33 HRAS NF1 NRAS
41 11.28 HRAS JAK2 PTPN11
42 11.25 HRAS NRAS
43 11.24 HRAS PTPN11
44 11.19 HRAS NRAS
45 11.18 HRAS NRAS
46
Show member pathways
11.17 HRAS NRAS
47 11.17 HRAS JAK2 NRAS
48 11.15 HRAS PTPN11
49
Show member pathways
11.11 HRAS NRAS
50 11.06 CSF2 HRAS NF1

GO Terms for Myelodysplastic Myeloproliferative Cancer

Biological processes related to Myelodysplastic Myeloproliferative Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon guidance GO:0007411 9.61 HRAS NRAS PTPN11
2 cytokine-mediated signaling pathway GO:0019221 9.56 CSF2 CSF3R JAK2 PTPN11
3 platelet-derived growth factor receptor signaling pathway GO:0048008 9.46 JAK2 PTPN11
4 regulation of long-term neuronal synaptic plasticity GO:0048169 9.4 HRAS NF1
5 interleukin-6-mediated signaling pathway GO:0070102 9.37 JAK2 PTPN11
6 Ras protein signal transduction GO:0007265 9.33 HRAS NF1 NRAS
7 regulation of myeloid cell differentiation GO:0045637 9.32 CSF2 CSF3R
8 epidermal growth factor receptor signaling pathway GO:0007173 9.13 HRAS NRAS PTPN11
9 MAPK cascade GO:0000165 9.02 CSF2 HRAS JAK2 NF1 NRAS

Molecular functions related to Myelodysplastic Myeloproliferative Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.46 HRAS JAK2 NRAS RARS
2 insulin receptor substrate binding GO:0043560 8.96 JAK2 PTPN11
3 peptide hormone receptor binding GO:0051428 8.62 JAK2 PTPN11

Sources for Myelodysplastic Myeloproliferative Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....